🎯 Background & Rationale
Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) is the gold standard for mediastinal and hilar lymph node sampling. Conventionally, a single needle is used for all passes at various stations. However, downtime occurs while the cytology team processes specimens between passes, potentially prolonging anesthesia duration and overall operating room (OR) utilization. This study addresses whether introducing a second needle can expedite the procedure enough to offset the added material cost and environmental impact.
👥 Study Design & Population
- Study Type: Prospective, single-blind, multi-center, randomized controlled trial.
- Population: 126 adult patients undergoing EBUS-TBNA for mediastinal and hilar lymph node sampling.
- Intervention: Randomized to either a 1-needle strategy or a 2-needle strategy.
📈 Methodology & Rigor
The trial randomized 126 patients to evaluate procedural efficiency.
- Primary Outcome: Time per needle pass.
- Secondary Outcomes: Cost-benefit analysis, diagnostic yield, next-generation sequencing (NGS) sufficiency, and carbon/environmental impact.
- Analytic Rigor: The authors incorporated a customizable economic model to help individual centers weigh the time-savings against equipment costs based on institutional anesthesia rates, needle prices, and expected passes per node.
🔬 Key Findings [or Planned Endpoints]
- Time per Pass: The two-needle group achieved significantly faster individual needle passes (56.2 ± 14.3 vs. 82.1 ± 21.9 s; p < 0.001).
- Total Procedure Time: There was no statistically significant difference in total procedure time between the two groups (22.2 ± 9.1 vs. 24.7 ± 12.5 min; p = 0.101).
- Passes & Yield: More needle passes were performed in the two-needle group (16.9 ± 6.5 vs. 13.9 ± 6.1; p = 0.004), with no difference in the number of lymph node stations sampled. Overall diagnostic yield (96.0%) and NGS sufficiency in cancer cases (93.6%) showed no significant differences between the arms.
- Economic/Environmental: Using a second needle increases immediate material costs and carbon footprint, though the authors’ model allows centers to calculate exact break-even thresholds.
⚖️ Critical Appraisal
- Internal Validity: The multi-center, randomized controlled design reduces single-center bias, and blinding the appropriate personnel helps mitigate performance bias.
- External Validity: While the dual-needle approach successfully reduced time per pass, it did not translate into a statistically significant reduction in total procedure time. This suggests that bottlenecks elsewhere in the workflow (e.g., rapid on-site evaluation [ROSE] processing, scope navigation, or patient positioning) may limit the macroscopic time savings of a second needle.
- Confounders: Variations in ROSE turnaround times, pathology processing workflows, and proceduralist experience across multi-center sites could influence individual pass-to-pass intervals.
💡 The Clinical Bottom Line
Using a second needle during EBUS-TBNA speeds up individual needle passes without compromising diagnostic yield or NGS sufficiency, but it does not automatically reduce overall procedure time. Interventional pulmonologists and bronchoscopy suite directors should use the study’s economic model to weigh institutional anesthesia costs and needle expenses before mandating a dual-needle protocol as a standard cost-saving maneuver.